@article{6b14f803bc664109a2e0392914e18f02,
title = "Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A gynecologic oncology group trial",
abstract = "Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.",
author = "Maurie Markman and Blessing, {John A.} and Koen DeGeest and Mark Morgan and Look, {Katherine Y.} and Herzog, {Thomas J.} and Rose, {Peter G.}",
note = "Funding Information: This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517). The following Gynecologic Oncology Group institutions participated in this study: Duke University Medical Center, Walter Reed Army Medical Center, Emory University Clinic, Hospital of the University of Pennsylvania, University of North Carolina School of Medicine, Indiana University Medical Center, Tufts New England Medical Center, Rush–Presbyterian–St. Lukes Medical Center, Cleveland Clinic Foundation, State University of New York at Stony Brook, Pennsylvania Hospital, Washington University School of Medicine, Cooper Hospital University Medical Center, Fox Chase Cancer Center, University of Oklahoma Health Science Center, University of Chicago, Tacoma General Hospital, Thomas Jefferson University Hospital, and Case Western Reserve University.",
year = "1999",
month = dec,
doi = "10.1006/gyno.1999.5640",
language = "English (US)",
volume = "75",
pages = "444--446",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",
}